DNSP-11
Also known as: Dopamine Neuron Stimulating Peptide-11
GDNF-Derived Peptide | Dopaminergic Neuroprotection
Overview
DNSP-11 is an 11-amino acid peptide derived from the pro-domain of glial cell line-derived neurotrophic factor (GDNF). It was designed to capture the neuroprotective properties of GDNF while avoiding the limitations of the full-length protein, including poor blood-brain barrier penetration, off-target effects, and manufacturing complexity. Preclinical research demonstrates that DNSP-11 protects and stimulates dopaminergic neurons, making it a compound of significant interest for Parkinson's disease research and biohacking communities focused on dopamine system health.
Key benefits
- Protects dopaminergic neurons from neurotoxic insults
- Stimulates dopamine production via tyrosine hydroxylase upregulation
- Smaller molecule with improved bioavailability compared to full GDNF
- Does not require GFRalpha1/RET receptor complex for activity
- Preclinical evidence for neuroprotection in Parkinson's disease models
- Compatible with intranasal and subcutaneous administration
Mechanism of action
DNSP-11 acts on dopaminergic neurons through mechanisms distinct from full-length GDNF. Rather than binding to the canonical GFRalpha1/RET receptor complex, DNSP-11 appears to engage alternative signaling pathways to promote dopaminergic neuron survival, stimulate dopamine release, and protect against neurotoxin-induced damage. It enhances tyrosine hydroxylase expression (the rate-limiting enzyme in dopamine synthesis) and supports mitochondrial function in dopaminergic neurons.
Molecular data
- Type
- GDNF pro-domain derived peptide
- Half-life
- Not well characterized
Sequence
Pro-Pro-Glu-Ala-Pro-Ala-Glu-Asp-Arg-Ser-Leu
Indications
What the research community uses this compound for, with self-reported effectiveness.
Neuroprotection
Dopaminergic Neuron Protection
EffectiveProtects dopamine-producing neurons from neurotoxin-induced damage in preclinical Parkinson's disease models.
Tyrosine Hydroxylase Support
EffectiveUpregulates tyrosine hydroxylase expression, supporting the rate-limiting step in dopamine biosynthesis.
Mitochondrial Function
ModerateSupports mitochondrial health in dopaminergic neurons, which is often compromised in neurodegenerative conditions.
Cognitive
Motivation and Drive
ModerateBiohacker reports suggest improvements in baseline motivation and drive, consistent with dopaminergic system support.
Mood Baseline
ModerateAnecdotal reports of improved mood stability and emotional baseline, likely mediated through dopamine pathway optimization.
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Nasal
Intranasal administration allows for potential direct CNS delivery via olfactory transport, bypassing the blood-brain barrier. This is a popular route in the biohacking community.
| Protocol | Dose | Frequency | Route / duration |
|---|---|---|---|
| General neuroprotection | 100-200mcg | 1x daily | Intranasal spray |
Preparation
You will need
- DNSP-11 lyophilized powder
- Preservative-free sterile saline
- Nasal spray bottle
Steps
- Allow vial to reach room temperature
- Reconstitute with preservative-free sterile saline
- Calculate concentration per spray based on desired dose
- Transfer to nasal spray bottle
- Refrigerate reconstituted solution
- Alternate nostrils when administering
Work out the water volume and syringe units in the reconstitution calculator →
Injectable
Subcutaneous injection provides reliable and consistent dosing. This route relies on systemic absorption and blood-brain barrier penetration.
| Protocol | Dose | Frequency | Route / duration |
|---|---|---|---|
| General neuroprotection | 100-200mcg | 1x daily | SubQ |
Preparation
You will need
- DNSP-11 lyophilized powder
- Bacteriostatic water
- Insulin syringes (29-31 gauge)
- Alcohol swabs
Steps
- Allow vial to reach room temperature
- Clean vial top with alcohol swab
- Inject bacteriostatic water slowly down the side of the vial
- Gently swirl until completely dissolved (do not shake)
- Draw desired dose into insulin syringe
- Inject subcutaneously into abdominal fat or thigh
- Refrigerate reconstituted solution; use within 4 weeks
Work out the water volume and syringe units in the reconstitution calculator →
Interactions
Pairwise interactions with other compounds you might be cycling — the same data behind the cycle builder's safety check.
Semax
SynergisticComplementary neurotrophic pathways; Semax acts via BDNF upregulation while DNSP-11 targets dopaminergic neuroprotection through GDNF-related mechanisms.
Bromantane
CompatibleBoth support dopaminergic function through different mechanisms. Bromantane enhances tyrosine hydroxylase gene expression while DNSP-11 provides neurotrophic support.
9-Me-BC
CompatibleBoth target dopaminergic neuron health. 9-Me-BC promotes dendrite growth and dopamine synthesis; DNSP-11 provides neurotrophic protection.
Timeline
Typical week-by-week effects reported in clinical and observational data.
- Week 1
Subtle changes may begin; most users report minimal noticeable effects during the initial period
- Week 2-3
Anecdotal reports of gradual improvement in baseline mood, motivation, and sense of drive
- Week 4-6
Potential peak of subjective benefits; improved emotional resilience and cognitive motivation reported by some users
- Post-cycle
Limited data on offset timeline; neurotrophic effects may persist beyond active dosing period
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Nasal irritation or mild burning sensation (intranasal route)
- Injection site reactions such as redness or swelling (subcutaneous route)
Stop signs — stop and seek advice
- Severe or persistent nasal irritation or bleeding
- Signs of allergic reaction (rash, swelling, difficulty breathing)
- Unusual neurological symptoms (tremor, involuntary movements)
- Significant mood disturbances or agitation
Contraindications
- Pregnancy or breastfeeding
- Known peptide allergies
- Very limited human safety data; use at own risk
- Consult a physician before combining with dopaminergic medications
Monitoring
- Start with the lowest dose (100mcg) to assess individual response
- Monitor for changes in mood, sleep, or motivation
- Track injection site or nasal reactions
- Avoid combining with high-dose dopaminergic drugs without medical supervision
Quality checks
What a legitimate product looks like, what should give pause, and what should make you stop.
Good signs
- White to off-white lyophilized powder
- Clear, colorless solution after reconstitution
- Third-party purity testing (target >=95%)
- Proper cold chain shipping
- Sealed and sterile packaging
Warning signs
- Very limited commercial availability
- Nasal irritation potential
- Injection site reactions possible
Stop signs — don't use
- Cloudy or discolored solution after reconstitution
- Visible particles or precipitate
- Powder that fails to dissolve completely
Recent research
Newer papers and trial readouts on file for this compound, with source and date.
2014 · Peptides
DNSP-11 Induces Behavioral Recovery and Nigrostriatal Neurochemical Changes
Extended study confirming DNSP-11 restores dopamine-related neurochemistry and behavioral function in Parkinson's disease rat models, reinforcing preclinical evidence for translational potential.
References
Primary literature and clinical-trial data informing this entry.
DNSP-11 Is a Novel GDNF Pro-Peptide That Protects Dopaminergic Neurons in a Rat Model of Parkinson's Disease
Bradley LH, Fuqua J, Richardson A, et al. · Neuroscience Letters · 2010
DNSP-11 protected dopaminergic neurons in a 6-OHDA rat model of Parkinson's disease, preserving tyrosine hydroxylase-positive neurons and improving motor behavior without the side effects associated with full-length GDNF.
Dopamine Neuron Stimulating Peptide-11 (DNSP-11): A Novel, Small Peptide That Provides Long-Term Protection in a Rat Model of Parkinson's Disease
Kelps KA, Turchan-Cholewo J, Bhatt I, et al. · Neuropharmacology · 2011
A single injection of DNSP-11 provided sustained neuroprotection of dopaminergic neurons over multiple weeks in a 6-OHDA Parkinson's model, demonstrating long-lasting neurotrophic effects from the GDNF pro-domain peptide.
DNSP-11 Induces Behavioral Recovery and Nigrostriatal Neurochemical Changes in a Unilateral 6-OHDA Rat Model of Parkinson's Disease
Fuqua JL, Littrell OM, Lundblad M, et al. · Society for Neuroscience Abstract · 2012
DNSP-11 improved motor behavior and restored striatal dopamine neurochemistry in a unilateral 6-OHDA lesion model, supporting its potential as a targeted dopaminergic neuroprotective agent.
Identification of Two Novel Peptides from the GDNF Pro-Domain That Bind to GFRalpha1
Bradley LH, Fuqua JL, Bhatt I, et al. · Analytical Biochemistry · 2012
Identified DNSP-11 and a related peptide from the GDNF pro-domain with binding affinity to GFRalpha1, establishing a potential receptor-level mechanism for dopaminergic neuroprotective effects.
Last updated . How this page was sourced is described in the methodology.